Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 27% Improvement Relative Risk Ventilation 7% ICU time -94% Hospitalization time -41% c19early.org/d Bychinin et al. NCT05092698 COVID-VIT Vitamin D RCT ICU Favors vitamin D Favors control
Effect of vitamin D3 supplementation on cellular immunity and inflammatory markers in COVID-19 patients admitted to the ICU
Bychinin et al., Scientific Reports, doi:10.1038/s41598-022-22045-y, COVID-VIT, NCT05092698 (history)
3 Nov 2022    Source   PDF   Share   Tweet
RCT ICU patients in Russia, showing significantly increased lymphocyte counts with treatment. Mortality was lower but without statistical significance. Authors used cholecalciferol. Calcifediol or calcitriol, which avoids several days delay in conversion, may be more appropriate and successful, especially with this very late stage usage. 40% of patients were on mechanical ventilation at baseline in the treatment group, compared to 30% in the placebo group.
Authors state that there has been 6 RCTs for COVID-19 and vitamin D, however there was at least 23 at the time of publication: [c19early.org].
Although the 27% lower mortality is not statistically significant, it is consistent with the significant 37% lower mortality [28‑44%] from meta analysis of the 59 mortality results to date.
risk of death, 26.9% lower, RR 0.73, p = 0.18, treatment 19 of 52 (36.5%), control 27 of 54 (50.0%), NNT 7.4.
risk of mechanical ventilation, 7.4% lower, RR 0.93, p = 0.68, treatment 33 of 52 (63.5%), control 37 of 54 (68.5%), NNT 20.
ICU time, 93.8% higher, relative time 1.94, p = 0.001, treatment 52, control 54.
hospitalization time, 41.4% higher, relative time 1.41, p = 0.007, treatment 52, control 54.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bychinin et al., 3 Nov 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Russia, peer-reviewed, 7 authors, average treatment delay 9.0 days, dosage 60,000IU day 1, 5,000IU days 2-7, 8, 5,000IU days 9-14, 15, 5,000IU days 16-21, 22, 5,000IU days 23-28, trial NCT05092698 (history) (COVID-VIT).
Contact: drbychinin@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit